發(fā)布時間：2018-04-11 04:13

  本文選題：miR-192 + 胃腫瘤�。� 參考：《安徽醫(yī)科大學》2017年碩士論文

【摘要】：目的為了探索miR-192-5p在體內能否通過調控核苷酸切除修復(NER)途徑中ERCC3和ERCC4蛋白表達逆轉胃癌細胞的順鉑耐藥性。方法采用基因芯片微陣列方法檢測胃癌順鉑耐藥細胞SGC7901/DDP和親本細胞SGC7901中LncRNA、mRNA和miRNA的表達差異。通過生物信息學預測軟件分析核酸切除修復蛋白ERCC3和ERCC4的mRNA中存在miR-192-5p的靶向結合位點。利用慢病毒在SGC7901/DDP細胞中穩(wěn)定上調miR-192-5p的表達、在SGC7901細胞中穩(wěn)定下調miR-192-5p的表達,應用qRT-PCR驗證轉染后miR-192-5p的表達水平。免疫蛋白印記技術(Western blot)方法檢測上調和下調miR-192-5p表達后細胞內ERCC3和ERCC4的表達。用四甲基偶氮唑鹽微量酶反應比色法(MTT)檢測調控miR-192-5p表達后細胞的順鉑耐藥性。將穩(wěn)定表達miR-192-5p的胃癌細胞、空載對照細胞和未轉細胞構建人胃癌裸鼠皮下移植瘤模型,腹腔灌注順鉑,測量各組瘤體的生長曲線及瘤體重量,免疫組化檢測ERCC3和ERCC4在瘤體內的表達。結果基因芯片檢測結果提示,SGC7901/DDP和SGC7901細胞中存在多個LncRNA、mRNA和miRNA的表達差異。通過生物學軟件分析這些異常表達的基因可能與順鉑耐藥相關,其中miR-192-5p在SGC7901/DDP中的表達較SGC7901中明顯降低,ERCC3和ERCC4的mRNA中存在miR-192-5p的靶向結合位點。上調miR-192-5p后,細胞內ERCC3和ERCC4的表達下調,順鉑的敏感性增強;下調miR-192-5p后,細胞內ERCC3和ERCC4的表達上調,順鉑的耐藥性增強。動物模型實驗表明,上調miR-192-5p后,瘤體內ERCC3和ERCC4的表達下調,瘤體對順鉑化療的敏感性提高,而下調miR-192-5p表達后,瘤體內ERCC3和ERCC4的表達上調,瘤體對順鉑耐藥。結論MiR-192-5p通過調控NER途徑中ERCC3和ERCC4表達影響胃癌細胞的順鉑耐藥性
[Abstract]:Objective to investigate whether miR-192-5p can reverse cisplatin resistance in gastric cancer cells by regulating the expression of ERCC3 and ERCC4 protein in the nucleotide excision repair pathway.Methods cDNA microarray was used to detect the expression of LncRNA-mRNA and miRNA in cisplatin resistant gastric cancer cell line SGC7901/DDP and parental cell SGC7901.Bioinformatics prediction software was used to analyze the existence of targeted miR-192-5p binding sites in ERCC3 and ERCC4 mRNA.Lentivirus was used to steadily up-regulate the expression of miR-192-5p in SGC7901/DDP cells and down-regulate the expression of miR-192-5p in SGC7901 cells. QRT-PCR was used to verify the expression level of miR-192-5p after transfection.The expression of ERCC3 and ERCC4 in the cells after up-regulation and down-regulation of miR-192-5p expression was detected by Western blot.The cisplatin resistance of cells regulated by miR-192-5p was detected by microenzyme reaction of tetramethylazolium.Gastric cancer cells expressing miR-192-5p stably, unloaded control cells and untransformed cells were used to construct subcutaneous transplanted tumor model of human gastric cancer in nude mice. Cisplatin was infused intraperitoneally to measure the growth curve and weight of tumor in each group.The expression of ERCC3 and ERCC4 in the tumor was detected by immunohistochemistry.Results the results of gene chip analysis showed that there were differences in mRNA and miRNA expression of LncRNAs in SGC7901 / DDP and SGC7901 cells.The abnormal expression of these genes may be related to cisplatin resistance by biological software. The expression of miR-192-5p in SGC7901/DDP is significantly lower than that in mRNA of SGC7901 and ERCC3 and ERCC4 have targeted miR-192-5p binding sites.After upregulation of miR-192-5p, the expression of ERCC3 and ERCC4 was down-regulated, and the sensitivity of cisplatin was enhanced. After down-regulation of miR-192-5p, the expression of ERCC3 and ERCC4 was up-regulated, and the resistance of cisplatin was enhanced.After up-regulation of miR-192-5p, the expression of ERCC3 and ERCC4 was down-regulated, and the sensitivity of tumor to cisplatin chemotherapy was increased. After down-regulation of miR-192-5p, the expression of ERCC3 and ERCC4 was up-regulated, and the tumor was resistant to cisplatin.Conclusion MiR-192-5p affects cisplatin resistance of gastric cancer cells by regulating the expression of ERCC3 and ERCC4 in NER pathway.
【學位授予單位】：安徽醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R735.2

【參考文獻】

相關期刊論文 前3條

1 黃娜娜;張逸寅;顧康生;;順鉑耐藥人胃癌細胞SGC-7901的耐藥特性的研究[J];安徽醫(yī)科大學學報;2015年03期

2 張芳;李洋;吳蘅;齊康;尤嘉琮;李雪冰;祖玲玲;潘振華;王玉麗;李永文;李穎;王珉;沈旺;周清華;;MiR-192靶向負調控Bim表達誘導肺癌順鉑耐藥[J];中國肺癌雜志;2014年05期

3 張逸寅;顧康生;;DNA修復率預測晚期胃癌含鉑化療方案療效的研究[J];臨床腫瘤學雜志;2013年09期

，

本文編號：1734375